Key facts
- This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2023, 06:50.
Dror Bashan - 19 Oct 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)
- Reporting relationship
- PRESIDENT AND CEO, Director
- Issuer ticker
- PLX
- Reported as of
- 19 Oct 2023
- Net transaction value
- +$90,484
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2023, 06:50:07 UTC
- Prior SEC filing
- 17 Aug 2023
- Next SEC filing
- 04 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dror Bashan
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 20 Oct 2023.
Change
- Previous filing in this sequence was filed on 17 Aug 2023.
- Current net transaction value: +$90,484.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLX
transaction
Common Stock
Purchase
- Transaction value
- $67,742
- Shares
- +48,387
- Change %
- +71%
- Price
- $1.40
- Shares after
- 116,387
- Date
- 19 Oct 2023
- Ownership
- Direct
PLX
transaction
Common Stock
Purchase
- Transaction value
- $22,742
- Shares
- +16,129
- Change %
- +14%
- Price
- $1.41
- Shares after
- 132,516
- Date
- 19 Oct 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.